Should I buy or sell Penumbra stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PEN shares. View PEN analyst ratings or view top-rated stocks .

What is Penumbra's stock price target for 2024?

9 Wall Street research analysts have issued 1-year price targets for Penumbra's stock. Their PEN share price targets range from $240.00 to $376.00. On average, they predict the company's stock price to reach $304.45 in the next twelve months. This suggests a possible upside of 50.2% from the stock's current price. View analysts price targets for PEN or view top-rated stocks among Wall Street analysts .

How have PEN shares performed in 2024?

Penumbra's stock was trading at $251.54 at the beginning of the year. Since then, PEN stock has decreased by 19.4% and is now trading at $202.72. View the best growth stocks for 2024 here .

When is Penumbra's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our PEN earnings forecast .

How can I listen to Penumbra's earnings call?

Penumbra will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) issued its quarterly earnings data on Thursday, February, 22nd. The company reported $0.76 EPS for the quarter, beating analysts' consensus estimates of $0.71 by $0.05. The business had revenue of $284.68 million for the quarter, compared to analysts' expectations of $286.62 million. Penumbra had a trailing twelve-month return on equity of 7.49% and a net margin of 8.59%. The firm's revenue for the quarter was up 28.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.16 EPS.

What ETFs hold Penumbra's stock?

ETFs with the largest weight of Penumbra (NYSE:PEN) stock in their portfolio include Fidelity Disruptive Medicine ETF (FMED) , Motley Fool Small-Cap Growth ETF (TMFS) , First Trust Indxx Medical Devices ETF (MDEV) , MFAM Small-Cap Growth ETF (MFMS) , First Trust Health Care AlphaDEX Fund (FXH) , SPDR S&P Health Care Equipment ETF (XHE) , ROBO Global Healthcare Technology and Innovation ETF (HTEC) and ProShares Metaverse ETF (VERS) .

What guidance has Penumbra issued on next quarter's earnings?

Penumbra updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com . Adam Elsesser has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA) , Intuitive Surgical (ISRG) , AbbVie (ABBV) , Tesla (TSLA) , Alibaba Group (BABA) , Johnson & Johnson (JNJ) , Netflix (NFLX) , UnitedHealth Group (UNH) , Boeing (BA) and DexCom (DXCM) .

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.49%), Congress Asset Management Co. MA (0.07%), Norden Group LLC (0.05%), State of Michigan Retirement System (0.02%), Diversified Trust Co (0.02%) and Artemis Investment Management LLP (0.00%). Insiders that own company stock include Adam Elsesser , Arani Bose , Bridget O'rourke , Don W Kassing, Harpreet Grewal , James Robert Pray , Johanna Roberts , Surbhi Sarna and Thomas Wilder . View institutional ownership trends .

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:PEN

Penumbra (PEN) Stock Price, News & Analysis

→ The only accurate crypto trading system I know … (From Weiss Ratings) (Ad)

Free PEN Stock Alerts

$203.05

+1.21 (+0.60%)

(As of 04/19/2024 ET)

Compare

Today's Range: $199.38
▼
$204.04
50-Day Range: $201.98
▼
$273.27
52-Week Range: $180.93
▼
$348.67

Volume: 338,648 shs
Average Volume: 343,339 shs
Market Capitalization: $7.86 billion

P/E Ratio: 87.90
Dividend Yield: N/A
Price Target: $304.45

Get Penumbra alerts:

Penumbra MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.78 Rating Score
Upside/Downside: 50.2% Upside
$304.45 Price Target
Short Interest: Healthy
4.99% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.17
Upright™ Environmental Score
News Sentiment: 1.17
Based on 3 Articles This Week
Insider Trading: Selling Shares
$2.37 M Sold Last Quarter
Proj. Earnings Growth: 39.65%
From $2.85 to $3.98 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.94 out of 5 stars

Medical Sector

15th out of 911 stocks

Surgical & Medical Instruments Industry

2nd out of 97 stocks

4.4

Analyst's Opinion

Consensus Rating
Penumbra has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Penumbra has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
4.99% of the outstanding shares of Penumbra have been sold short.
Short Interest Ratio / Days to Cover
Penumbra has a short interest ratio ("days to cover") of 5.6.
Change versus previous month
Short interest in Penumbra has recently decreased by 2.03%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Penumbra does not currently pay a dividend.
Dividend Growth
Penumbra does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Penumbra has received a 51.31% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Surgical instruments" product. See details.
Environmental Sustainability
The Environmental Impact score for Penumbra is -1.17.

2.3

News and Social Media Coverage

News Sentiment
Penumbra has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Penumbra this week, compared to 6 articles on an average week.
Search Interest
Only 3 people have searched for PEN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Penumbra to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,369,903.00 in company stock.
Percentage Held by Insiders
Only 5.30% of the stock of Penumbra is held by insiders.
Percentage Held by Institutions
88.88% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Penumbra are expected to grow by 39.65% in the coming year, from $2.85 to $3.98 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Penumbra is 87.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.45.
Price to Earnings Ratio vs. Sector
The P/E ratio of Penumbra is 87.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 215.55.
Price to Earnings Growth Ratio
Penumbra has a PEG Ratio of 2.06. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Penumbra has a P/B Ratio of 6.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About Penumbra Stock (NYSE:PEN)

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

PEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PEN Stock News Headlines

April 4, 2024 | insidertrades.com

Insider Selling: Penumbra, Inc. (NYSE:PEN) Director Sells 170 Shares of Stock

April 4, 2024 | insidertrades.com

Insider Selling: Penumbra, Inc. (NYSE:PEN) EVP Sells 600 Shares of Stock

April 19, 2024 | Crypto Swap Profits (Ad)

He Is Giving Away Bitcoin

April 16, 2024 | americanbankingnews.com

Critical Review: Penumbra (NYSE:PEN) vs. ProSomnus (NASDAQ:OSA)

April 9, 2024 | finance.yahoo.com

Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024

April 9, 2024 | prnewswire.com

Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024

April 9, 2024 | msn.com

Total solar eclipse 2024: Watch video and see photos of the sky spectacle

April 8, 2024 | msn.com

Celestial event: What you need to know about today's total solar eclipse

April 19, 2024 | Crypto Swap Profits (Ad)

He Is Giving Away Bitcoin

April 7, 2024 | msn.com

Monday’s Solar Eclipse: Chicago to Witness Partial Sun Obscuration, Southern Illinois to Experience Totality

April 5, 2024 | uk.investing.com

Penumbra director sells $37,940 in company stock

April 5, 2024 | news.yahoo.com

What is an umbra? A penumbra? Here's some terms to know ahead of the 2024 solar eclipse

April 5, 2024 | msn.com

‘Nervous’ parents beg NYC officials to do more to protect kids during solar eclipse

April 5, 2024 | msn.com

Edge of solar eclipse path of totality may slightly shift, experts warn

April 4, 2024 | finance.yahoo.com

Insider Sell: EVP, General Counsel & Secretary Johanna Roberts Sells Shares of Penumbra Inc ...

April 4, 2024 | msn.com

Eclipse 2024: What to expect here in Michigan

April 3, 2024 | msn.com

How do flat-earthers explain a total solar eclipse?

April 3, 2024 | msn.com

2024 solar eclipse: Updates, live video and photos

April 2, 2024 | msn.com

A little-known Illinois village is eclipse capital, USA; Here's how they're preparing for this year's event

April 2, 2024 | msn.com

Your guide to the 2024 solar eclipse in Philly, beyond

April 2, 2024 | msn.com

What are the main differences between a total solar eclipse and a partial eclipse?

April 2, 2024 | msn.com

Everything you need to know about the total solar eclipse

April 1, 2024 | msn.com

When was the last time New Jersey had a total solar eclipse? And when's the next one?

April 1, 2024 | yahoo.com

Totality, corona, Baily's beads: Do you know your solar eclipse terminology?

March 31, 2024 | msn.com

Hey Ray - Become an eclipse expert

March 30, 2024 | msn.com

Solar eclipse in Upstate NY: NASA video explains mystery of who gets most totality

March 29, 2024 | msn.com

Airzoo plans free event to celebrate solar eclipse on April 8

See More Headlines

Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/19/2024
Next Earnings (Confirmed): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NYSE:PEN
CUSIP: N/A
CIK: 1321732
Web: www.penumbrainc.com
Phone: (510) 748-3200
Fax: 510-748-3232
Employees: 4,200
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $304.45
High Stock Price Target: $376.00
Low Stock Price Target: $240.00
Potential Upside/Downside: +49.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.78
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.31
Trailing P/E Ratio: 87.90
Forward P/E Ratio: 71.25
P/E Growth: 2.06
Net Income: $90.95 million
Net Margins: 8.59%
Pretax Margin: 7.52%
Return on Equity: 7.49%
Return on Assets: 5.60%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 6.06
Quick Ratio: 3.49

Sales & Book Value

Annual Sales: $1.06 billion
Price / Sales: 7.42
Cash Flow: $2.75 per share
Price / Cash Flow: 73.80
Book Value: $30.55 per share
Price / Book: 6.65

Miscellaneous

Outstanding Shares: 38,704,000
Free Float: 36,653,000
Market Cap: $7.86 billion
Optionable: Optionable
Beta: 0.51

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Adam Elsesser (Age 62)
Co-Founder, Chairman, President & CEO
Comp: $601.62k
Dr. Arani Bose M.D. (Age 62)
Co-Founder & Director
Comp: $37.5k
Ms. Maggie S. Yuen (Age 51)
Chief Financial Officer
Comp: $660.98k
Mr. Lambert Shiu (Age 43)
Chief Accounting Officer
Comp: $539.15k
Ms. Johanna Roberts (Age 52)
Executive VP, General Counsel & Secretary
Comp: $655.75k
Mr. Ben Sorci
Executive Vice President of Operations
Mr. Pankaj Tiwari
Executive VP & Chief Information Officer
Ms. Jee Hamlyn-Harris
Investor Relations Officer
Mr. Ben Tompkins
Executive Vice President of Development
Ms. Gita Barry
President of Immersive Healthcare

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PEN shares.
View PEN analyst ratings or view top-rated stocks.
What is Penumbra's stock price target for 2024?: 9 Wall Street research analysts have issued 1-year price targets for Penumbra's stock. Their PEN share price targets range from $240.00 to $376.00. On average, they predict the company's stock price to reach $304.45 in the next twelve months. This suggests a possible upside of 50.2% from the stock's current price.
View analysts price targets for PEN or view top-rated stocks among Wall Street analysts.
How have PEN shares performed in 2024?: Penumbra's stock was trading at $251.54 at the beginning of the year. Since then, PEN stock has decreased by 19.4% and is now trading at $202.72.
View the best growth stocks for 2024 here.
When is Penumbra's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our PEN earnings forecast.
How can I listen to Penumbra's earnings call?: Penumbra will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Penumbra's earnings last quarter?: Penumbra, Inc. (NYSE:PEN) issued its quarterly earnings data on Thursday, February, 22nd. The company reported $0.76 EPS for the quarter, beating analysts' consensus estimates of $0.71 by $0.05. The business had revenue of $284.68 million for the quarter, compared to analysts' expectations of $286.62 million. Penumbra had a trailing twelve-month return on equity of 7.49% and a net margin of 8.59%. The firm's revenue for the quarter was up 28.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.16 EPS.

What ETFs hold Penumbra's stock?: ETFs with the largest weight of Penumbra (NYSE:PEN) stock in their portfolio include Fidelity Disruptive Medicine ETF (FMED), Motley Fool Small-Cap Growth ETF (TMFS), First Trust Indxx Medical Devices ETF (MDEV), MFAM Small-Cap Growth ETF (MFMS), First Trust Health Care AlphaDEX Fund (FXH), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and ProShares Metaverse ETF (VERS).
What guidance has Penumbra issued on next quarter's earnings?: Penumbra updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.
What is Adam Elsesser's approval rating as Penumbra's CEO?: 57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.
What other stocks do shareholders of Penumbra own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).
Who are Penumbra's major shareholders?: Penumbra's stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.49%), Congress Asset Management Co. MA (0.07%), Norden Group LLC (0.05%), State of Michigan Retirement System (0.02%), Diversified Trust Co (0.02%) and Artemis Investment Management LLP (0.00%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends.
How do I buy shares of Penumbra?: Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PEN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Penumbra (PEN) Stock Price, News & Analysis

Penumbra MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Penumbra Stock (NYSE:PEN)

PEN Stock Price History

PEN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PEN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™